Drug Device Combination Products Market Report by Product, Application, End User, and Region 2024-2032

The global drug device combination products market size reached US$ 155.3 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 284.9 Billion by 2032, exhibiting a growth rate (CAGR) of 6.7% during 2024-2032. Technological advancements in drug delivery systems, rising prevalence of chronic diseases, increasing geriatric population, surging demand for personalized medicine, strategic collaborations by key players, expanding healthcare expenditure, preference for minimally invasive procedures, and expanding product applications in diverse therapeutic areas are some of the factors supporting the market growth.

Drug Device Combination Products Market Analysis:

• Major Market Drivers: As per the drug device combination products market analysis, the rising prevalence of chronic diseases and the requirement for more efficient and convenient treatment alternatives are propelling the demand for drug-device combination products. The drug device combination products market growth is also stimulated by the burgeoning geriatric population worldwide, which has surged the demand for new healthcare approaches, as elderly people are producing more lifestyle-related health problems. Additionally, companies have increasingly adopted approaches to personalized medicine, including drug delivery gadgets for targeted therapy, which is further positively contributing to the drug device combination products market share. Other factors that have fueled the drug device combination products market outlook include regulatory support and economic incentives for combination product development, as well as expanding healthcare spending in developing countries.
• Key Market Trends: As per the drug device combination products market research, the most substantial trends in the drug-device combination products are the growing interest in wearable drug delivery devices for the patient's mobility and quality of life improvement. Another factor that propels the drug device combination products market value is the increasing use of smart devices to control patient adherence and therapy response and adjust the dose and treatment regime as necessary in real-time. In line with this, the incorporation of digital technology into products and their ability to utilize the Internet of Things (IoT) increases patient engagement and outcomes monitoring, which is further driving the drug device combination products market demand. Apart from this, the progression of three-dimensional (3D) printing technology creates new opportunities for individualizing device manufacturing based on patient anatomy and needs, which is contributing to the drug device combination products market forecast.
• Geographical Trends: As per the drug device combination products market research report, North America is the leading region in the industry due to the developed healthcare infrastructure, extensive investment in research and development (R&D), and lenient regulation. Besides this, the high health expenditure supported by the massive burden of diseases in the region has driven adoption of new and emerging treatment alternatives, which is further accelerating the drug device combination products market price. Europe is a close follower in the drug device combination products market segmentation, given its strong healthcare systems and focus on quality and safety. On the other hand, the Asia-Pacific region is an increasingly growing market supported by rising health expenditure, increasing knowledge of modern treatment approaches, and a growing number of chronic conditions, which is further boosting the drug device combination products market revenue.
• Competitive Landscape: As per the drug device combination products market statistics, some of the key players in the market include Abbott Laboratories, Baxter International Inc., Bayer AG, Becton Dickinson and Company, Boston Scientific Corporation, GlaxoSmithKline plc, Johnson & Johnson, Medtronic plc, Novartis AG, Smith & Nephew plc, Stryker Corporation, Terumo Corporation, etc.
• Challenges and Opportunities: As per the drug device combination products market overview, the market has many challenges, including the high level of regulatory requirements, which can lead to an increase in development time and as a result, increase the cost. Ensuring the compatibility of the drug and device, which must meet all safety and effectiveness standards, is a big difficulty. Many of the same factors present opportunities for innovation. In particular, new approaches to increasing the efficiency of devices and increasing the convenience for the patient. A favorable opportunity is also to replenish the market for countries with a potential demand for advanced medical solutions that are not being solved.

Drug Device Combination Products Market Trends:

Technological Advancements in Drug Delivery Systems

New drug delivery systems, including auto-injectors, inhalers, and infusion pumps, are transforming the way healthcare is administered, making it more precise, convenient, and effective. Precise and targeted drug delivery allows patients to achieve the desired therapeutic effect with a minimal likelihood of suffering from adverse drug reactions. For example, using auto-injectors has significantly changed the way patients take medication daily by allowing users to administer it themselves in a comfortable and easy way. This drug delivery system assists with treatment compliance and hospitalization costs cutting. Sophisticated inhalers for respiratory problems, such as those equipped with a dose counter or digital sensors, provide feedback and monitoring, giving patients the power to manage drug administration independently.

Increasing Prevalence of Chronic Diseases

The burgeoning prevalence of chronic diseases, such as cardiovascular disorders (CVDs), diabetes, and cancer, is one of the primary factors that have surged the demand for customized and innovative drug device combination products for complex therapeutic needs. Based on the National Institute of Health (NIH), chronic conditions accounted for 74% of all deaths in 2019; a substantial rise on 67% of deaths in 2010. Mortality data illustrate high prevalence's of chronic conditions among populations. In Australia, for example, Australian Institute of Health and Welfare reports 47% of Australians have at least one chronic disease with 20% bearing 2 or more.

Rising Geriatric Population and Demand for Personalized Medicine

The growing number of geriatric people worldwide and extended human life expectancy will make it challenging to deal with gerontology allowing for the need for medicine implemented and remedy methods, which is further supporting the drug device combination products market. According to the World Health Organization (WHO), 1 of 6 individuals will be aged 60 and above by 2030; at that point, the total number will reach 1.4 billion. By 2050, the number of people in that age category will be 2.1 billion, while the group aged 80 and even older will climb to 426 million, which is three times more in comparison to 2020.

Drug Device Combination Products Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the global, regional, and country levels for 2024-2032. Our report has categorized the market based on product, application, and end user.

Breakup by Product:

• Drug Eluting Stents
• Transdermal Patches
• Infusion Pumps
• Drug Eluting Balloon
• Inhalers
• Others

Transdermal patches represents the leading market segment

The report has provided a detailed breakup and analysis of the market based on the product. This includes drug eluting stents, transdermal patches, infusion pumps, drug eluting balloon, inhalers, and others. According to the report, transdermal patches represented the largest segment.

The transdermal patches segment is driven by the increasing demand for non-invasive drug delivery methods that offer convenience, pain reduction, and improved patient compliance. With an emphasis on patient-centric healthcare solutions, transdermal patches provide a viable alternative to traditional oral medications and injections, particularly for individuals with needle phobia or difficulty swallowing pills. Additionally, the segment is propelled by advancements in patch technology, including the development of novel adhesive formulations and permeation enhancers, which enhance drug absorption through the skin, leading to more efficient and consistent drug delivery. Moreover, the rising prevalence of chronic diseases, such as cardiovascular disorders, diabetes, and pain-related conditions, drives the demand for transdermal patches as they offer sustained release formulations that ensure continuous therapeutic levels of medication over an extended period, reducing the frequency of dosing and minimizing fluctuations in drug concentration in the bloodstream.

Breakup by Application:

• Cardiovascular
• Diabetes
• Cancer Treatment
• Respiratory Diseases
• Others

Respiratory diseases represents the leading market segment

The report has provided a detailed breakup and analysis of the market based on the application. This includes cardiovascular, diabetes, cancer treatment, respiratory diseases, and others. According to the report, respiratory diseases represented the largest segment.

The respiratory diseases segment is driven by the increasing prevalence of respiratory disorders globally, exacerbated by factors such as air pollution, smoking, and aging populations. Moreover, lifestyle changes, including sedentary habits and poor dietary choices, contribute to the rising incidence of respiratory ailments such as asthma, chronic obstructive pulmonary disease (COPD), and respiratory infections. Additionally, urbanization and industrialization lead to heightened exposure to environmental pollutants, allergens, and occupational hazards, further escalating the burden of respiratory diseases. Furthermore, the growing awareness about the adverse health effects of indoor and outdoor air pollution drives demand for respiratory therapies and preventive measures, fostering market growth. Moreover, advancements in diagnostic techniques, including imaging modalities and biomarker assays, enable early detection and intervention for respiratory conditions, driving market expansion through improved patient outcomes and treatment efficacy.

Breakup by End User:

• Hospitals
• Ambulatory Surgical Centers
• Others

Hospitals represents the leading market segment

The report has provided a detailed breakup and analysis of the market based on the end user. This includes e- hospitals, ambulatory surgical centers, and others. According to the report, hospitals represented the largest segment.

The hospitals segment is driven by the increasing demand for advanced medical devices and technologies to enhance patient care, optimize clinical outcomes, and improve operational efficiency. Hospitals are investing in state-of-the-art equipment such as imaging systems, surgical robots, and patient monitoring devices to meet the growing healthcare needs of their patient populations. Additionally, the adoption of electronic health records (EHRs) and health information systems is on the rise, driven by the need for integrated data management solutions that streamline workflows, facilitate informed decision-making, and ensure compliance with regulatory requirements. Furthermore, hospitals are prioritizing investments in infection control and patient safety measures, spurred by the ongoing challenges posed by healthcare-associated infections (HAIs) and the need to mitigate risks in clinical environments. This includes the implementation of advanced disinfection technologies, antimicrobial surfaces, and real-time monitoring systems to prevent the spread of infections and safeguard patient well-being.

Breakup by Region:

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa

North America leads the market, accounting for the largest drug device combination products market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America represents the largest regional market for drug device combination products.

The North American region is driven by the increasing prevalence of chronic diseases, such as diabetes, CVDs, and cancer. With a growing aging population and sedentary lifestyles contributing to the rise in chronic conditions, there's a heightened demand for innovative treatment solutions. This trend fuels the adoption of drug device combination products that offer enhanced efficacy and convenience in managing these complex health issues. Additionally, the region benefits from robust regulatory frameworks and streamlined approval processes, facilitating the development and commercialization of new combination therapies. Moreover, strategic collaborations between pharmaceutical companies, medical device manufacturers, and research institutions drive innovation and accelerate the pace of product development in North America. These collaborations leverage the region's strong research infrastructure and expertise to address unmet medical needs and capitalize on emerging market opportunities. Furthermore, the increasing healthcare expenditure in North America supports market growth by improving accessibility to advanced combination therapies and fostering investment in research and development initiatives.

Competitive Landscape:

• The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the major market players in the drug device combination products industry include Abbott Laboratories, Baxter International Inc., Bayer AG, Becton Dickinson and Company, Boston Scientific Corporation, GlaxoSmithKline plc, Johnson & Johnson, Medtronic plc, Novartis AG, Smith & Nephew plc, Stryker Corporation, Terumo Corporation, etc.

(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)

• The key players in the drug device combination products market are actively engaged in strategic initiatives to maintain their competitive edge and drive market growth. These initiatives include extensive research and development (R&D) efforts aimed at introducing novel combination therapies that offer improved therapeutic outcomes and patient convenience. Additionally, companies are focusing on expanding their product portfolios through acquisitions, partnerships, and collaborations with other industry stakeholders. These strategic alliances enable companies to leverage complementary expertise, technologies, and resources to accelerate product development and market penetration. Moreover, key players are investing in marketing and promotional activities to raise awareness about their products and enhance their market presence. Furthermore, efforts are being made to strengthen regulatory compliance and quality assurance processes to ensure product safety and efficacy. Additionally, companies are exploring opportunities in emerging markets by establishing local manufacturing facilities and distribution networks to cater to the growing demand for combination products in these regions.

Drug Device Combination Products Market News:

• In June 2020: Abbott announced the launch of its new drug device combination product, the FreeStyle Libre 2 system, in the United States. This system integrates Abbott's continuous glucose monitoring (CGM) technology with a wearable sensor and a mobile app, allowing individuals with diabetes to monitor their glucose levels continuously without the need for fingerstick tests. The FreeStyle Libre 2 system offers improved accuracy and reliability compared to previous models, providing patients with real-time insights into their glucose levels and helping them make more informed decisions about their diabetes management.
• In August 2020: Medtronic announced the FDA approval of its MiniMed 770G insulin pump system for use in children aged 2 to 6 years with type 1 diabetes. This drug device combination product combines an insulin pump with a continuous glucose monitoring (CGM) system, enabling automated insulin delivery based on real-time glucose readings. The MiniMed 770G system features advanced algorithms that help stabilize blood sugar levels and reduce the risk of hypoglycemia in young children, providing caregivers with peace of mind and improving the overall management of pediatric diabetes.

Key Questions Answered in This Report:

• How has the global drug device combination products market performed so far, and how will it perform in the coming years?
• What are the drivers, restraints, and opportunities in the global drug device combination products market?
• What is the impact of each driver, restraint, and opportunity on the global drug device combination products market?
• What are the key regional markets?
• Which countries represent the most attractive drug device combination products market?
• What is the breakup of the market based on the product?
• Which is the most attractive product in the drug device combination products market?
• What is the breakup of the market based on the application?
• Which is the most attractive application in the drug device combination products market?
• What is the breakup of the market based on the end user?
• Which is the most attractive end user in the drug device combination products market?
• What is the competitive structure of the market?
• Who are the key players/companies in the global drug device combination products market?